BREAKING: CDC, FDA call for immediate halt on Johnson & Johnson vaccine
This comes as cases of blood clots forming after receiving the Johnson & Johnson vaccine continue to rise
FDA and CDC officials discuss the Johnson & Johnson COVID vaccine. This video was previously live-streamed and has since ended.
LINCOLN, Neb. (KLKN)- The CDC and FDA just announced that they are calling for the immediate pause on the use of Johnson & Johnson’s single-dose vaccine.
As of Monday, April 12, over 6.8 million doses of the J&J vaccine have been administered in the U.S. On Friday, the state of Nebraska reported 31,700 had been given statewide.
COVID NEWS CONTINUED: Nebraska pausing use of Johnson & Johnson vaccine
The CDC and FDA are going to be reviewing data over the six discovered cases in the U.S. of a rare and severe type of blood clot that developed about two weeks after the patient received the J&J vaccine. According to FDA’s Dr. Peter Marks these blood clots have been seeing in women ages 18 to 48. In the six identified cases, blood clot symptoms presented within six to 13 days of being vaccinated.
Health officials theorize that these clots are caused by a unique immune response to the vaccine that actives the platelets, which form the rare blood clots.
“I’d like to stress, these events appear to be extremely rare. However, COVID-19 vaccine safety is a top priority for the federal government and we take all reports of adverse events following vaccination very seriously,” commented Acting FDA Commissioner Dr. Janet Woodcock.
COVID NEWS CONTINUED: More than 218,500 COVID shots given locally
“[The] CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance,” read a joint CDC and FDA statement that was issued on Tuesday morning. “[The] FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.”
CDC Principal Deputy Director Dr. Anne Schuchat said, “I know there are people who have gotten the vaccine, who are probably very concerned for people who got the vaccine, more than a month ago, very low. At this time, for people who recently got the vaccine within the last couple of weeks, they should be aware, to look for any of these symptoms.”
Symptoms to be on the lookout for include severe headaches, abdominal pain, leg pain, or shortness of breath. The CDC says these symptoms differ from the “mild flu-like symptoms… that many people experienced in a couple of days after receiving the vaccine.”
Johnson & Johnson issued the following statement:
“The safety and well-being of the people who use our products is our number one priority. We share all adverse event reports about individuals receiving our COVID-19 vaccine, along with our assessment of these reports, with health authorities in compliance with regulatory standards.
We are aware that thromboembolic events including those with thrombocytopenia have been reported with COVID-19 vaccines. At present, no clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine.
We continue to work closely with experts and regulators to assess the data and support the open communication of this information to healthcare professionals and the public.”
Again, health officials have only identified six cases of these rare clots out of the nearly 7 million Johnson & Johnson vaccines given. The decision to pause the usage of this vaccine is to educate health care provides on the signs of these clots and how to best treat them.